70 related articles for article (PubMed ID: 30736150)
1. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
Chilton R
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):345-349. PubMed ID: 30736150
[TBL] [Abstract][Full Text] [Related]
2. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Rosenstock J; Kahn SE; Johansen OE; Zinman B; Espeland MA; Woerle HJ; Pfarr E; Keller A; Mattheus M; Baanstra D; Meinicke T; George JT; von Eynatten M; McGuire DK; Marx N;
JAMA; 2019 Sep; 322(12):1155-1166. PubMed ID: 31536101
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
[TBL] [Abstract][Full Text] [Related]
4. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
6. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Kadowaki T; Wang G; Rosenstock J; Yabe D; Peng Y; Kanasaki K; Mu Y; Mattheus M; Keller A; Okamura T; Johansen OE; Marx N
Diabetol Int; 2021 Jan; 12(1):87-100. PubMed ID: 33479584
[TBL] [Abstract][Full Text] [Related]
7. Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Rosenstock J; Kolkailah AA; McGuire DK; Espeland MA; Mattheus M; Pfarr E; Lund SS; Marx N;
Diabetes Obes Metab; 2023 Jun; 25(6):1453-1463. PubMed ID: 36700416
[TBL] [Abstract][Full Text] [Related]
8. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
Patorno E; Schneeweiss S; Gopalakrishnan C; Martin D; Franklin JM
Diabetes Care; 2019 Dec; 42(12):2204-2210. PubMed ID: 31239281
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Espeland MA; Pratley RE; Rosenstock J; Kadowaki T; Seino Y; Zinman B; Marx N; McGuire DK; Andersen KR; Mattheus M; Keller A; Weber M; Johansen OE
Diabetes Obes Metab; 2021 Feb; 23(2):569-580. PubMed ID: 33185002
[TBL] [Abstract][Full Text] [Related]
10. Comparison of gliclazide
Mohan V; Wangnoo S; Das S; Dhediya R; Gaurav K
World J Diabetes; 2022 Dec; 13(12):1168-1183. PubMed ID: 36578872
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
13. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
15. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
16. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.
Gallwitz B
Diabetes Metab Syndr Obes; 2013; 6():1-9. PubMed ID: 23319869
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
Chen Y; Ning G; Wang C; Gong Y; Patel S; Zhang C; Izumoto T; Woerle HJ; Wang W
J Diabetes Investig; 2015 Nov; 6(6):692-8. PubMed ID: 26543544
[TBL] [Abstract][Full Text] [Related]
18. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.
Gallwitz B
Ther Adv Endocrinol Metab; 2013 Jun; 4(3):95-105. PubMed ID: 23730503
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
